Compound ID | 489

Update compound information

ME2303

Class: DNA synthesis inhibitor (anthracycline)

Details of activity: Has reduced cardiotoxicity compared with previous anthracyclines- was in clinical trials for cancer.
Institute where first reported: Meiji Seika Kaisha (Meiji Seika Pharma., Japan)
Year first mentioned: 1991
Highest developmental phase: Phase 2
Development status: Inactive
Chemical structure(s):
Click here for structure editor
Molecular weight: 704.65
Iso. SMILES: C[C@H]1[C@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)COC(=O)CCCCCC(=O)O)O)F)O)O
InChI Key: PQMIPLRIRFVQJZ-QBYYVRQOSA-N
Can. SMILES: C[C@H]1[C@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=O)C5=C(C=CC=C5C4=O)OC)C(=C32)O)O)(C(=O)COC(=O)CCCCCC(=O)O)O)F)O)O
InChI: InChI=1S/C34H37FO15/c1-14-27(40)32(45)26(35)33(49-14)50-18-12-34(46,19(36)13-48-21(39)10-5-3-4-9-20(37)38)11-16-23(18)31(44)25-24(29(16)42)28(41)15-7-6-8-17(47-2)22(15)30(25)43/h6-8,14,18,26-27,32-33,40,42,44-46H,3-5,9-13H2,1-2H3,(H,37,38)/t14-,18-,26+,27+,32-,33-,34-/m0/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/115362
Citations:
  • https://www.researchgate.net/publication/21151988_Effects_of_anthracycline_derivatives_on_hepatic_neoplastic_nodules_of_Lewis_lung_carcinoma_and_colon_adenocarcinoma_26

  • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.